Vaccine mediated protection against Zika virus-induced congenital disease
Richner, Justin M.
Jagger, Brett W.
Fontes-Garfias, Camila R
Dowd, Kimberly A.
Caine, Elizabeth A.
Nunes, Bruno Tardelli Diniz
Medeiros, Daniele Barbosa de Almeida
Muruato, Antonio E.
Foreman, Bryant M.
Barrett, Alan D.
Weaver, Scott C.
Vasconcelos, Pedro Fernando da Costa
Rossi, Shannan L.
Mysorekar, Indira U.
Pierson, Theodore C.
Diamond, Michael S.
The emergence of Zika virus (ZIKV) and its association with congenital malformations has prompted the rapid development of vaccines. Although efficacy with multiple viral vaccine platforms has been established in animals, no study has addressed protection during pregnancy. We tested in mice two vaccine platforms, a lipid nanoparticle-encapsulated modified mRNA vaccine encoding ZIKV prM and E genes and a live-attenuated ZIKV strain encoding an NS1 protein without glycosylation, for their ability to protect against transmission to the fetus. Vaccinated dams challenged with a heterologous ZIKV strain at embryo day 6 (E6) and evaluated at E13 showed markedly diminished levels of viral RNA in maternal, placental, and fetal tissues, which resulted in protection against placental damage and fetal demise. As modified mRNA and live-attenuated vaccine platforms can restrict in utero transmission of ZIKV in mice, their further development in humans to prevent congenital ZIKV syndrome is warranted.
xmlui.dri2xhtml.METS-1.0.item-citationRICHNER, Justin M et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell, v. 170, n. 2, p. 273-283, July 2017.
xmlui.dri2xhtml.METS-1.0.item-decsPrimaryZika virus / fisiologia
Infecção pelo Zika virus / imunologia
Infecção pelo Zika virus / prevenção & controle
Infecção pelo Zika virus / virologia
Vacinas Virais / administração & dosagem
Vacinas Virais / imunologia
Vacinas de Subunidades / administração & dosagem
Vacinas de Subunidades / imunologia
Feto / virologia
Camundongos Endogâmicos C57BL